E-LIB Suche - Ergebnisse für: Yap, C.W.

1

Search for dark matter and other new phenomena in events wi..:

KÜÇÜK, HİLAL ; Poettgen, R ; Zwalinski, L...
adf2173f-5fa1-47ec-a812-529f18703a58. , 2018

Link: https://doi.org/10.1007/..

2

Search for a Structure in the B-s(0) pi(+/-) Invariant Mass..:

Nakamura, K ; Zwalinski, L ; zur Nedden, M...
cb6f85ed-a787-4b77-9f23-2b0e08cd78d8. , 2018

Link: https://doi.org/10.1103/..

3

Technical Design Report for the LUXE Experiment:

Abramowicz, H ; Soto, M. Almanza ; Altarelli, M...
http://arxiv.org/abs/2308.00515. , 2023

Link: http://arxiv.org/abs/230..

4

Optimizing vancomycin dosing in chronic kidney disease by d..:

Dorajoo, S.R ; Winata, C.L ; Fen Goh, J.H...
Dorajoo, S.R., Winata, C.L., Fen Goh, J.H., Ooi, S.T., Somani, J., Yeoh, L.Y., Lee, S.Y., Yap, C.W., Chan, A., Chae, J.-W. (2019). Optimizing vancomycin dosing in chronic kidney disease by deriving and implementing a web-based tool using a population pharmacokinetics analysis. Frontiers in Pharmacology 10 (JUN) : 641. ScholarBank@NUS Repository.. , 2019

Link: https://scholarbank.nus...

5

Measurement of (W +/- )W +/- vector-boson scattering and li..:

D'Onofrio, M ; Zwalinski, L ; zur Nedden, M...
8634de32-c903-4f8f-8339-3ed8714f1a69. , 2017

Link: https://doi.org/10.1103/..

6

Measurements of Z gamma and Z gamma gamma production in pp ..:

Heinrich, J. J ; Zwalinski, L ; Zurzolo, G...
0a612f31-ab5a-49bd-a0d5-37d96f0d6d00. , 2016

Link: https://doi.org/10.1103/..

7

Evaluation of the sensitivity of scout radiographs on unenh..:

Yap, W W ; Belfield, J C ; Bhatnagar, P..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474095. , 2012

Link: http://www.ncbi.nlm.nih...

8

The Netherlands Arrhythmogenic Cardiomyopathy Registry: des..:

Bosman, L.P. (L. P.) ; Verstraelen, T.E. (T. E.) ; van Lint, F.H.M. (F. H.M.)...
http://repub.eur.nl/pub/120253. , 2019

Link: http://repub.eur.nl/pub/..

9

Targeting myeloid chemotaxis to reverse prostate cancer the..:

Guo, C ; Sharp, A ; Gurel, B...
doi:10.1038/s41586-023-06696-z. , 2024

Link: https://doi.org/10.1038/..

10

Ruxolitinib versus best available therapy for PV intolerant..:

Harrison, C ; Nangalia, J ; Boucher, R...
British Journal of Haematology, 2023, 201 pp. 88 - 88. , 2024

Link: https://repository.icr.a..

11

SPIRIT and CONSORT extensions for early phase dose-finding ..:

Espinasse, A ; Solovyeva, O ; Dimairo, M...
https://eprints.whiterose.ac.uk/197947/1/e068173.full.pdf. , 2023

Link: https://eprints.whiteros..

12

Development of consensus-driven SPIRIT and CONSORT extensio..:

Solovyeva, O ; Dimairo, M ; Weir, C.J...
https://eprints.whiterose.ac.uk/201317/1/s12916-023-02937-0.pdf. , 2023

Link: https://eprints.whiteros..

13

Enhancing reporting quality and impact of early phase dose-..:

Yap, C ; Solovyeva, O ; de Bono, J...
https://eprints.whiterose.ac.uk/204564/1/CONSORT-DEFINE%20bmj-2023-076387.full.pdf. , 2023

Link: https://eprints.whiteros..

14

Phase 1, dose-escalation study of guadecitabine (SGI-110) i..:

Papadatos-Pastos, D ; Yuan, W ; Pal, A...
https://discovery.ucl.ac.uk/id/eprint/10152373/1/Parmar_Phase%201%20dose-escalation%20study%20of%20guadecitabine_VoR.pdf. , 2022

Link: https://discovery.ucl.ac..

15

Phase 1, dose-escalation study of guadecitabine (SGI-110) i..:

Papadatos-Pastos, D ; Yuan, W ; Pal, A...
Journal for ImmunoTherapy of Cancer. , 2022

Link: https://repository.icr.a..